Low fixed dose rasburicase for tumour lysis syndrome prophylaxis and treatment is feasible and efficacious in the management of haematologic malignancies
- DOI
- 10.1177/10781552261459597
- Published
- 2026-06-25
- Container
- Journal of Oncology Pharmacy Practice
- Publisher
- SAGE Publications
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1177/10781552261459597,
title = {Low fixed dose rasburicase for tumour lysis syndrome prophylaxis and treatment is feasible and efficacious in the management of haematologic malignancies},
author = {Taylor Mackie and Joshua Tobin and Vivien Chan and Michael Whordley and Elizabeth Luo and Karl Winckel and Jane Dunsdon and Marissa Ryan},
year = {2026},
journal = {Journal of Oncology Pharmacy Practice},
doi = {10.1177/10781552261459597},
url = {https://doi.org/10.1177/10781552261459597}
}RIS
TY - JOUR TI - Low fixed dose rasburicase for tumour lysis syndrome prophylaxis and treatment is feasible and efficacious in the management of haematologic malignancies AU - Taylor Mackie AU - Joshua Tobin AU - Vivien Chan AU - Michael Whordley AU - Elizabeth Luo AU - Karl Winckel AU - Jane Dunsdon AU - Marissa Ryan PY - 2026 JO - Journal of Oncology Pharmacy Practice DO - 10.1177/10781552261459597 UR - https://doi.org/10.1177/10781552261459597 ER -
APA
Mackie, T., Tobin, J., Chan, V., Whordley, M., Luo, E., Winckel, K., Dunsdon, J., & Ryan, M. (2026). Low fixed dose rasburicase for tumour lysis syndrome prophylaxis and treatment is feasible and efficacious in the management of haematologic malignancies. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552261459597
Source records
- crossref · retrieved 2026-11-10T13:26:20.546Z